// //
* Click Here to download our Order Form
The recently passed CARES Act includes an important section that significantly reforms the regulatory framework for OTC drugs and makes important changes to how FDA regulates drugs marketed under an OTC Monograph. It is likely to yield greater OTC access to drug ingredients with strong safety profiles. It also allows for changes to be implemented by administrative orders instead of the current cumbersome notice and comment rule-making process – a major change that should speed up the drug review process. It also provides the incentive of 18-month market exclusivity and establishes user fee requirements.
Join this session by expert speaker Norma Skolnik, where she will illustrate why it’s essential for all marketers of OTC drugs to learn about these changes.
Session Highlights:-
Why Should You Attend:-
Anyone involved in the marketing of OTC drugs must learn about how these important changes to FDA’s OTC Monograph process will impact their company’s drug products. Sunscreen manufacturers need to understand how this Act impacts their products. Understanding how the new CARES Act Reform changes will affect current and future products and replace the current OTC drug rulemaking process is critical for OTC industry stakeholders.
Who Should Attend:-